Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Queensland Health
McKinsey
Federal Trade Commission
Healthtrust
Johnson and Johnson
Baxter
Farmers Insurance
Teva

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019487

« Back to Dashboard

NDA 019487 describes IMODIUM A-D, which is a drug marketed by J And J Consumer Inc and is included in three NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the IMODIUM A-D profile page.

The generic ingredient in IMODIUM A-D is loperamide hydrochloride. There are eleven drug master file entries for this compound. One hundred and twenty suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride profile page.
Summary for 019487
Tradename:IMODIUM A-D
Applicant:J And J Consumer Inc
Ingredient:loperamide hydrochloride
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 019487
Suppliers and Packaging for NDA: 019487
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IMODIUM A-D loperamide hydrochloride SOLUTION;ORAL 019487 NDA Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division 50580-134 50580-134-44 120 mL in 1 BOTTLE (50580-134-44)
IMODIUM A-D loperamide hydrochloride SOLUTION;ORAL 019487 NDA Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division 50580-134 50580-134-04 120 mL in 1 BOTTLE (50580-134-04)

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:SOLUTION;ORALStrength1MG/5ML
Approval Date:Mar 1, 1988TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:SUSPENSION;ORALStrength1MG/7.5ML
Approval Date:Jul 8, 2004TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Fuji
QuintilesIMS
Novartis
US Army
Daiichi Sankyo
McKinsey
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot